|
1.
|
|
11 p, 618.2 KB |
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities : Laboratory tools for an early and differential diagnosis
/
Moreno-Castaño, Ana Belén (Hospital Clínic i Provincial de Barcelona) ;
Fernández, Sara (Hospital Clínic i Provincial de Barcelona) ;
Ventosa, Helena (Hospital Clínic i Provincial de Barcelona) ;
Palomo, Marta (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ramos, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Fernández De Larrea, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Penack, Olaf (Charité Universitätsmedizin Berlin, Germany) ;
Nicolás, J.M. (Hospital Clínic i Provincial de Barcelona) ;
Téllez, Adrian (Hospital Clínic i Provincial de Barcelona) ;
Escolar, Gines (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Castro Rebollo, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Diaz-Ricart, Maribel (Hospital Clínic i Provincial de Barcelona)
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. [...]
2023 -  10.1136/jitc-2022-006365
Journal for immunotherapy of cancer, Vol. 11 Núm. 4 (april 2023)
|
|
|
2.
|
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, Manel (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 - 10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
|
3.
|
|
14 p, 308.2 KB |
At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation : A Unicentric, Safe, and Feasible Program
/
Ruiz-Boy, Sonia (Hospital Clínic i Provincial de Barcelona) ;
Pedraza, Alexandra (Hospital Clínic i Provincial de Barcelona) ;
Prat, Marta (Hospital Clínic i Provincial de Barcelona) ;
Salas, María Queralt (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Carcelero, Ester (Hospital Clínic i Provincial de Barcelona) ;
Riu-Viladoms, G (Hospital Clínic i Provincial de Barcelona) ;
Suárez-Lledó Grande, María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Monge-Escartín, Inés (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez-Lobato, Luís Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-Roca, Alexandra (Hospital Clínic i Provincial de Barcelona) ;
Rovira Argelagués, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez, Carmen (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gallego, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Urbano-Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez, Juan (Hospital Clínic i Provincial de Barcelona) ;
Marcos, María Ángeles (Hospital Clínic i Provincial de Barcelona) ;
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona)
Cytomegalovirus (CMV) infection is a relevant cause of morbimortality in patients receiving allogeneic stem cell transplantation (allo-HCT). Foscarnet (FCN) is an effective drug against CMV administered intravenously and usually on an inpatient basis. [...]
2023 - 10.3390/ph16121741
Pharmaceuticals, Vol. 16 Núm. 12 (december 2023) , p. 1741
|
|
|
4.
|
|
9 p, 406.9 KB |
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
/
Saad, Ayman (The Ohio State University) ;
Lamb, Lawrence (University of Alabama at Birmingham) ;
Wang, Tao (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Spellman, Stephen (National Marrow Donor Program/Be the Match) ;
Couriel, Daniel R (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin (Anderson Cancer Center) ;
Pidala, Joseph (H. Lee Moffitt Cancer Center) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Agrawal, Vaibhav (Indiana University School of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Beitinjaneh, Amer (University of Miami) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Buchbinder, David Kyle (Children's Hospital of Orange County) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Cairo, Mitchell S. (New York Medical College) ;
Castillo, Paul A. (UF Health Shands Children's Hospital) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Diaz, Miguel Angel (Hospital Infantil Universitario Nino Jesus) ;
Farhan, Shatha (Henry Ford Hospital Bone Marrow Transplant Program) ;
Floisand, Yngvar (The National Hospital) ;
Frangoul, Haydar A. (Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute) ;
Gadalla, Shahinaz M. (National Cancer Institute) ;
Gajewski, James (Consultant at Lu Daopei Hospital) ;
Gale, Robert Peter (Imperial College London) ;
Gandhi, Manish (Mayo Clinic) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Hamilton, Betty (Cleveland Clinic Taussig Cancer Institute) ;
Hematti, Peiman (University of Wisconsin Hospital and Clinics) ;
Hildebrandt, Gerhard C. (University of Kentucky) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Khandelwal, Pooja (Cincinnati Children's Hospital Medical Center) ;
Lazaryn, Aleksandr (H. Lee Moffitt Cancer Center) ;
MacMillan, Margaret (University of Minnesota Blood and Marrow Transplant Program) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Mehta, Parinda A. (Cincinnati Children's Hospital Medical Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center) ;
Olsson, Richard (Uppsala University) ;
Patel, Sagar (Cleveland Clinic Foundation) ;
Qayed, Muna (Emory University School of Medicine) ;
Rangarajan, Hemalatha G. (Nationwide Children's Hospital) ;
Reshef, R. (Columbia University Medical Center) ;
Ringden, O. (Karolinska Institutet (Estocolm, Suècia)) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Schouten, H.C. (Academische Ziekenhuis) ;
Schultz, K.R. (The University of British Columbia) ;
Seo, S. (Dokkyo Medical University) ;
Shaffer, B.C. (Memorial Sloan Kettering Cancer Center) ;
Solh, M. (Northside Hospital) ;
Teshima, T. (Hokkaido University Hospital) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Verdonck, L.F. (Isala Clinic) ;
Vij, R. (Washington University School of Medicine) ;
Waller, E.K. (Emory University) ;
William, B. (The Ohio State University) ;
Wirk, B. (Seattle Cancer Care Alliance) ;
Yared, J.A. (University of Maryland) ;
Yu, L.C. (Children's Hospital/Louisiana State University Medical Center) ;
Arora, M. (University of Minnesota Medical Center) ;
Hashmi, S. (Mayo Clinic) ;
Universitat Autònoma de Barcelona
Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). [...]
2019 - 10.1016/j.bbmt.2019.05.007
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1875-1883
|
|
|
5.
|
|
11 p, 2.0 MB |
Development of a Novel Anti-CD19 Chimeric Antigen Receptor : A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
/
Castella, Maria (Hospital Clínic i Provincial de Barcelona) ;
Boronat, Anna (Hospital Clínic i Provincial de Barcelona) ;
Martín-Ibáñez, Raquel (Universitat de Barcelona) ;
Rodríguez, Vanina (Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS) ;
Suñé, Guillermo (Hospital Clínic i Provincial de Barcelona) ;
Caballero, Miguel (Hospital Clínic i Provincial de Barcelona) ;
Marzal, Berta (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Amill, Lorena (Hospital Clínic i Provincial de Barcelona) ;
Martín-Antonio, B. (Hospital Clínic i Provincial de Barcelona) ;
Castaño Cardoso, Julio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Balagué, Olga (Hospital Clínic i Provincial de Barcelona) ;
González-Navarro, Europa Azucena (Hospital Clínic i Provincial de Barcelona) ;
Serra-Pages, Carles (Hospital Clínic i Provincial de Barcelona) ;
Engel, Pablo (Hospital Clínic i Provincial de Barcelona) ;
Vilella, Ramon (Hospital Clínic i Provincial de Barcelona) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Tabera, Jaime (Institut d'Investigació Biomèdica Sant Pau) ;
Canals, Josep M. (Universitat de Barcelona) ;
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Baumann, Tycho (Hospital Clínic i Provincial de Barcelona) ;
Vilarrodona, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Trias, Esteve (Hospital Clínic i Provincial de Barcelona) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urbano-Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Yagüe, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Galán, Patricia (Centro de Investigación Biomédica en Red de Cáncer) ;
Rives, Susana (Institut de Recerca Sant Joan de Déu) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). [...]
2019 - 10.1016/j.omtm.2018.11.010
Molecular Therapy. Methods & Clinical Development, Vol. 12 (15 2019) , p. 134-144
|
|
|
6.
|
|
10 p, 523.7 KB |
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
/
Im, A. (University of Pittsburgh/UPMC Hillman Cancer Center) ;
Rashidi, A. (University of Minnesota) ;
Wang, T. (Medical College of Wisconsin) ;
Hemmer, M. (Medical College of Wisconsin) ;
MacMillan, M.L. (University of Minnesota) ;
Pidala, J. (H. Lee Moffitt Cancer Center and Research Institute) ;
Jagasia, M. (Vanderbilt University Medical Center) ;
Pavletic, S. (National Cancer Institute of Bethesda) ;
Majhail, N.S. (Cleveland Clinic Taussig Cancer Institute) ;
Weisdorf, D. (University of Minnesota) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Agrawal, Vaibhav (Indiana University School of Medicine) ;
Al-Homsi, A.S. (New York University Langone Medical Center) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Askar, Medhat (Baylor University Medical Center) ;
Auletta, Jeffery J (Nationwide Children's Hospital) ;
Bashey, A. (Blood and Marrow Transplant Program at Northside Hospital) ;
Beitinjaneh, Amer (University of Miami) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Byrne, M. (Vanderbilt University Medical Center) ;
Cahn, J.Y. (CHU Grenoble Alpes) ;
Cairo, M. (New York Medical College) ;
Castillo, P. (UF Health Shands Children's Hospital) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Ciurea, S. (The University of Texas MD Anderson Cancer Center) ;
Daly, A. (Tom Baker Cancer Center) ;
Perez, M.A.D. (Hospital Infantil Universitario Nino Jesus) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Gadalla, S.M. (NIH-NCI Clinical Genetics Branch) ;
Gale, R. (Imperial College London) ;
Ganguly, S. (University of Kansas Health System) ;
Gergis, U. (Thomas Jefferson University) ;
Hanna, R. (Cleveland Clinic Foundation) ;
Hematti, Peiman (University of Wisconsin) ;
Herzig, R. (University of Kentucky Chandler Medical Center) ;
Hildebrandt, G.C. (University of Kentucky) ;
Lad, D.P. (Postgraduate Institute of Medical Education and Research) ;
Lee, C. (University of Utah) ;
Lehmann, L. (Dana-Farber Cancer Institute/Boston Children's Hospital) ;
Lekakis, L. (University of Miami) ;
Kamble, R.T. (Baylor College of Medicine) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Khandelwal, P. (University of Cincinnati) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Murthy, H.S. (Mayo Clinic) ;
Nishihori, T. (Moffitt Cancer Center) ;
O'Brien, T.A. (Sydney Children's Hospital) ;
Olsson, R.F. (Uppsala University) ;
Patel, S.S. (University of Utah) ;
Perales, M.A. (Memorial Sloan Kettering Cancer Center) ;
Prestidge, T. (Starship Children's Hospital (Auckland, Nova Zelanda)) ;
Qayed, M. (Emory University School of Medicine) ;
Romee, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Schoemans, H. (University Hospitals Leuven (Bèlgica)) ;
Seo, S. (Dokkyo Medical University) ;
Sharma, A. (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Solh, M. (Northside Hospital) ;
Strair, R. (Rutgers University) ;
Teshima, T. (Hokkaido University Hospital) ;
Urbano-Ispizua, Alvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Van der Poel, M. (Maastricht University Medical Center) ;
Vij, R. (Washington University School of Medicine) ;
Wagner, J.L. (Thomas Jefferson University) ;
William, B. (The Ohio State University) ;
Wirk, B. (Penn State Cancer Institute) ;
Yared, J.A. (University of Maryland) ;
Spellman, S.R. (Medical College of Wisconsin) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, B. K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. [...]
2020 - 10.1016/j.bbmt.2020.05.001
Biology of blood and marrow transplantation, Vol. 26 Núm. 8 (august 2020) , p. 1459-1468
|
|
|
7.
|
|
2 p, 458.6 KB |
Role of Hospital Exemption in Europe : position paper from the Spanish Advanced Therapy Network
/
Sanchez-Guijo, Fermin (Universidad de Salamanca) ;
Badimon, Lina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Avendaño Sola, Cristina (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Bueren, Juan (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Canals, Josep M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Delgadillo Duarte, Joaquin (Banc de Sang i Teixits) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Eguizábal, Cristina (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Fernández-Santos, María-Eugenia (Gregorio Marañón General University Hospital) ;
García-Olmo, Damián (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
González-Aseguinolaza, Gloria (Universidad de Navarra) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Martín, Francisco (Universidad de Granada. Departamento de Bioquímica y Biología Molecular III e Inmunología) ;
Mata, Rosario (Coordination Unit of the Andalusian Network for the Design and Translation of Advanced Therapies) ;
Montserrat, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Pérez-Martínez, Antonio (Universidad Autónoma de Madrid) ;
Pérez-Simón, José Antonio (Universidad de Sevilla. Department of Hematology) ;
Prosper, Felipe (Clínica Universidad de Navarra) ;
Urbano Ispizua, Álvaro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Zapata, Agustín G. (Complutense University. Faculty of Biology. Dept of Cell Biology) ;
Sureda, Anna (Universitat de Barcelona. Departament d'hematologia) ;
Moraleda, José María (University of Murcia) ;
Universitat Autònoma de Barcelona
2023 - 10.1038/s41409-023-01962-0
Bone marrow transplantation, Vol. 58 (march 2023) , p. 727-728
|
|
|
8.
|
|
14 p, 1.0 MB |
CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
/
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Barrera, Susana (Universidad de Salamanca) ;
Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Elliot, Natalina (John Radcliffe Hospital (Oxford, Regne Unit)) ;
O'Byrne, Sorcha (John Radcliffe Hospital (Oxford, Regne Unit)) ;
Wang, Guanlin (University of Oxford) ;
Rovira, Montse (University of Oxford) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-González, María (Universidad de Salamanca) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sorigue, Marc (Universitat Autònoma de Barcelona) ;
Bárcena, Paloma (Universidad de Salamanca) ;
Zanetti, S. R (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torrebadell, Montse (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Vega-Garcia, Nerea (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Rives, Susana (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Mallo, Maria del Mar (Universitat Autònoma de Barcelona) ;
Sole, F (Universitat Autònoma de Barcelona) ;
Mead, Adam J. (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Roberts, Irene (Oxford Biomedical Research Centre) ;
Thongjuea, Supat (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Psaila, Bethan (Oxford Biomedical Research Centre) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizúa, Alvaro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ribera, Jose-Maria (Universitat Autònoma de Barcelona) ;
Orfao, Alberto (Universidad de Salamanca) ;
Roy, Anindita (Oxford Biomedical Research Centre) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. [...]
2022 - 10.1182/blood.2021014840
Blood, Vol. 140 (july 2022) , p. 38-44
|
|
|
9.
|
|
20 p, 5.5 MB |
Il-15 enhances the persistence and function of bcma-targeting car-t cells compared to il-2 or il-15/il-7 by limiting car-t cell dysfunction and differentiation
/
Battram, Anthony M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bachiller, Mireia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lopez, Victor (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernandez de Larrea Rodriguez, Carlos (Universitat de Barcelona. Departament de Medicina) ;
Urbano-Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín-Antonio, B (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a year of receiving the therapy. [...]
2021 - 10.3390/cancers13143534
Cancers, Vol. 13 Núm. 14 (february 2021) , art. 3534
|
|
|
10.
|
|
7 p, 5.6 MB |
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
/
Ortiz-Maldonado, Valentín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Frigola, Gerard (Hospital Clínic i Provincial de Barcelona) ;
Español-Rego, Marta (Hospital Clínic i Provincial de Barcelona) ;
Balagué, Olga (Hospital Clínic i Provincial de Barcelona) ;
Martínez Cibrián, Núria (Hospital Clínic i Provincial de Barcelona) ;
Magnano, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Giné, Eva (Centro de Investigación Biomédica en Red de Cáncer) ;
Pascal, Mariona (Hospital Clínic i Provincial de Barcelona) ;
Correa, Juan G. (Hospital Clínic i Provincial de Barcelona) ;
Martínez-Roca, Alexandra (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Lozano, Miquel (Universitat de Barcelona. Departament de Medicina) ;
Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
López Guillermo, Armando (Universitat de Barcelona. Departament de Medicina) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Juan, Manel (Universitat de Barcelona. Departament de Medicina) ;
Delgado, Julio (Universitat de Barcelona. Departament de Medicina)
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter's transformation (RT). [...]
2022 - 10.3389/fonc.2022.828471
Frontiers in Oncology, Vol. 12 (31 2022) , p. 828471
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
